A new extension cohort study (Sehn et al., 2022) of pola+BR in relapsed/refractory DLBCL, 9.9% patients discontinued treatment due to serious sepsis in the pooled pola+BR cohort. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.